PriceTargets.com logo

Contineum Therapeutics - CTNM Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $29.25
  • Forecasted Upside: 116.67%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 1 Strong Buy Ratings
$13.50 As of 12/20/2024 06:16 PM ET
▲ +0.15 (1.12%)

This chart shows the closing price for CTNM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Contineum Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CTNM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CTNM

Analyst Price Target is $29.25
▲ +116.67% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Contineum Therapeutics in the last 3 months. The average price target is $29.25, with a high forecast of $32.00 and a low forecast of $25.00. The average price target represents a 116.67% upside from the last price of $13.50.

This chart shows the closing price for CTNM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in Contineum Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/7/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$32.00 ➝ $31.00
10/22/2024Baird R WUpgradeStrong-Buy
10/22/2024Robert W. BairdInitiated CoverageOutperform$32.00
8/14/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$30.00 ➝ $32.00
4/30/2024Royal Bank of CanadaInitiated CoverageOutperform$30.00
4/30/2024Morgan StanleyInitiated CoverageOverweight$25.00
4/30/2024Stifel NicolausInitiated CoverageBuy$29.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.50 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 2 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Contineum Therapeutics

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $13.50
Low: $13.00
High: $13.87

50 Day Range

MA: $15.73
Low: $13.30
High: $19.64

52 Week Range

Now: $13.50
Low: $12.33
High: $22.00

Volume

796,653 shs

Average Volume

85,236 shs

Market Capitalization

$348.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Contineum Therapeutics?

The following sell-side analysts have issued reports on Contineum Therapeutics in the last year: Baird R W, Morgan Stanley, Robert W. Baird, Royal Bank of Canada, and Stifel Nicolaus.
View the latest analyst ratings for CTNM.

What is the current price target for Contineum Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Contineum Therapeutics in the last year. Their average twelve-month price target is $29.25, suggesting a possible upside of 116.7%. Robert W. Baird has the highest price target set, predicting CTNM will reach $32.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $25.00 for Contineum Therapeutics in the next year.
View the latest price targets for CTNM.

What is the current consensus analyst rating for Contineum Therapeutics?

Contineum Therapeutics currently has 4 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CTNM will outperform the market and that investors should add to their positions of Contineum Therapeutics.
View the latest ratings for CTNM.

What other companies compete with Contineum Therapeutics?

Other companies that are similar to Contineum Therapeutics include Mesoblast, Travere Therapeutics, Intellia Therapeutics, Praxis Precision Medicines and Arvinas. Learn More about companies similar to Contineum Therapeutics.

How do I contact Contineum Therapeutics' investor relations team?

Contineum Therapeutics' physical mailing address is 10578 Science Center Drive, Suite 200, San Diego, CA 92121, United States. The company's listed phone number is (858) 333-5280 and its investor relations email address is [email protected]. The official website for Contineum Therapeutics is www.contineum-tx.com. Learn More about contacing Contineum Therapeutics investor relations.